Neumora Therapeutics, Inc. Common Stock

NMRANASDAQUSD
1.55 USD
0.01 (0.64%)🟢PRE MARKET (AS OF 04:01 AM EDT)
🟢Market: OPEN

Neumora Therapeutics, Inc. Common Stock (NMRA) trades at $1.55 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, NMRA trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Aug 26, 2026.

Open?$1.55
High?$1.55
Low?$1.55
Prev. Close?$1.56
Volume?68
Avg. Volume?714.6K
VWAP?$1.55
Rel. Volume?0.00x
Bid / Ask
Bid?$1.29 × 100
Ask?$1.83 × 100
Spread?$0.54
Midpoint?$1.56
Valuation & Ratios
Market Cap?293.1M
Shares Out?187.9M
Float?81.8M
Float %?44.2%
P/E Ratio?N/A
P/B Ratio?6.58
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Employees
63
Market Cap
281.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2023-09-15
Address
260 ARSENAL PLACE, SUITE 1
WATERTOWN, MA 02472
Phone: (857) 760-0900
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?-16.77Distress
Confidence?59%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?9.77%Elevated
Short Interest?8.0M
Days to Cover?13.4
Free Float81.8M
Avg Daily Volume596.2K
Settlement Date2026-08-14
Financial Health
Current Ratio?4.50Strong
Quick Ratio?4.50Strong
Cash Ratio?4.21Strong
Debt/Equity?1.19Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A
P/B?
Peers
100
S&P
28
6.58FAIR
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-1.1CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-477.9%WEAK
ROA?
S&P
3
-169.9%WEAK
Cash Flow & Enterprise
FCF?$-180520000
Enterprise Value?$229.2M
Fundamentals ratios updated end of day